Tandem Diabetes Care (NASDAQ:TNDM) Price Target Increased to $40.00 by Analysts at Stifel Nicolaus

Tandem Diabetes Care (NASDAQ:TNDM) had its target price boosted by Stifel Nicolaus from $37.00 to $40.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the medical device company’s stock. Stifel Nicolaus’ price objective suggests a potential upside of 16.75% from the company’s current price.

Other analysts have also issued reports about the stock. Citigroup upped their price target on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. StockNews.com raised shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research report on Friday. One analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $37.27.

Tandem Diabetes Care Stock Up 8.0 %

Shares of TNDM stock traded up $2.53 during trading on Tuesday, reaching $34.26. The company’s stock had a trading volume of 1,402,092 shares, compared to its average volume of 1,731,221. The company has a quick ratio of 3.02, a current ratio of 3.83 and a debt-to-equity ratio of 0.91. The business has a fifty day moving average price of $30.09 and a 200-day moving average price of $25.00. Tandem Diabetes Care has a one year low of $13.82 and a one year high of $40.74. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -9.93 and a beta of 1.11.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. The firm had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. Analysts anticipate that Tandem Diabetes Care will post -1.62 earnings per share for the current year.

Institutional Investors Weigh In On Tandem Diabetes Care

Large investors have recently bought and sold shares of the company. Eminence Capital LP grew its stake in Tandem Diabetes Care by 76.1% during the third quarter. Eminence Capital LP now owns 5,490,017 shares of the medical device company’s stock worth $114,028,000 after buying an additional 2,372,458 shares in the last quarter. Raymond James & Associates lifted its holdings in shares of Tandem Diabetes Care by 128.5% in the fourth quarter. Raymond James & Associates now owns 91,985 shares of the medical device company’s stock worth $2,721,000 after acquiring an additional 51,721 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Tandem Diabetes Care by 4.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 367,011 shares of the medical device company’s stock worth $7,623,000 after acquiring an additional 16,586 shares during the last quarter. Paradice Investment Management LLC lifted its holdings in shares of Tandem Diabetes Care by 23.9% in the third quarter. Paradice Investment Management LLC now owns 1,520,065 shares of the medical device company’s stock worth $31,572,000 after acquiring an additional 293,250 shares during the last quarter. Finally, Banque Pictet & Cie SA bought a new position in shares of Tandem Diabetes Care in the third quarter worth about $2,295,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.